Pathogenesis and treatment of mitochondrial disorders

Advances in Experimental Medicine and Biology

Volumn 652, Issue , 2009, Pages 139-170

  DiMauro, Salvatore ^a   Hirano, Michio ^b  

^a NewYork Presbyterian Hospital   (United States)

^b NONE

Author keywords

Energy failure; Gene therapy; Mitochondrial diseases; Oxidative stress; Pharmacological therapy; Respiratory chain defects; Symptomatic therapy

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE TRIPHOSPHATE; ANTICONVULSIVE AGENT; ARGININE; BEZAFIBRATE; CALCIUM ION; CORTICOSTEROID; DICHLOROACETIC ACID; DNA DIRECTED DNA POLYMERASE GAMMA; DYNAMIN; GANGLIOSIDE INDUCED DIFFERENTIATION PROTEIN 1; HELICASE; MITOCHONDRIAL DNA; MITOFUSIN 2; PLACEBO; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 1; PROTEIN OPA1; PROTEIN POLG2; PSYCHOTROPIC AGENT; REACTIVE OXYGEN METABOLITE; RIBOFLAVIN; TRANSCRIPTION FACTOR; UBIDECARENONE; UNCLASSIFIED DRUG; VALPROIC ACID;

ADENINE NUCLEOTIDE TRANSLOCASE GENE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOSOMAL DOMINANT OPTIC ATROPHY; AUTOSOMAL INHERITANCE; BARTH SYNDROME; CALCIUM HOMEOSTASIS; CHROMOSOME SEGREGATION; COENZYME Q10 DEFICIENCY; CONFERENCE PAPER; DISEASE CLASSIFICATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA REPLICATION; DOSE RESPONSE; DRUG MEGADOSE; DRUG TOLERABILITY; EYE SURGERY; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC CODE; GENETIC MANIPULATION; HETEROPLASMY; HUMAN; INTRACELLULAR SIGNALING; LACTIC ACIDOSIS; MELAS SYNDROME; MENTAL DISEASE; MERRF SYNDROME; MITOCHONDRIAL DNA DEPLETION SYNDROME; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL RESPIRATION; MITOFUSIN 2 GENE; MNGIE SYNDROME; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; MUTATOR GENE; MYOGLOBINURIA; NARP SYNDROME; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE METABOLISM; OPA1 GENE; PATHOGENESIS; PERIPHERAL NEUROPATHY; POINT MUTATION; PRIORITY JOURNAL; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA 1 GENE; PYRUVATE DEHYDROGENASE COMPLEX DEFICIENCY; SEIZURE; TISSUE SPECIFICITY; CLASSIFICATION; GENETICS; PATHOLOGY; REVIEW;

DNA, MITOCHONDRIAL; HUMANS; MITOCHONDRIAL DISEASES;

EID: 77950354207     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-90-481-2813-6_10     Document Type: Conference Paper

References (180)

1. Luft R, Ikkos D, Palmieri G, et al. A case of severe hypermetabolism of nonthyroid origin with a defect in the maintenance of mitochondrial respiratory control: A correlated clinical, biochemical, and morphological study. J Clin Invest. 1962;41:1776-1804.
2. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-1430. (Pubitemid 19008070)
3. Holt IJ, Harding AE, Morgan Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988;331:717-719. (Pubitemid 18062238)
4. Luft R. The development of mitochondrial medicine. Proc. Natl. Acad. Sci. USA 1994;91:8731-8738.
5. Gvozdjáková A, ed. Mitochondrial Medicine: Springer, 2008.
6. DiMauro S, Hirano M, Schon EA, eds. Mitochondrial Medicine. Abingdon, UK: Informa Healthcare, 2006.
7. Shy GM, Gonatas NK. Two childhood myopathies with abnormal mitochondria: I. Megaconial myopathy; II. Pleoconial myopathy. Brain 1966;89:133-158.
8. Shy GM, Gonatas NK. Human myopathy with giant abnormal mitochondria. Science 1964;145:493-496.
9. Engel WK, Cunningham CG. Rapid examination of muscle tissue: An improved trichrome stain method for fresh-frozen biopsy sections. Neurology 1963;13:919-923.
10. Shapira Y, Harel S, Russell A. Mitochondrial encephalomyopathies: a group of neuromuscular disorders with defects in oxidative metabolism. Isr. J. Med. Sci. 1977;13:161-164. (Pubitemid 8090523)
11. Mitomap. MITOMAP: A human mitochondrial genome database. http://www.mitomap.org. 2003.
12. Sproule D, KaufmannP. Mitochondrial encephalomyopathy, lactic acidosis and strokelike episodes (MELAS): A review of basic concepts, the clinical phenotype, and therapeutic management. Ann. NY Acad. Sci. 2008;1142:133-158.
13. Shanske S, Coku J, Lu J, et al. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome. Arch. Neurol. 2008;65: 368-372. (Pubitemid 351398522)
14. Manwaring N, Jones MM, Wang JJ, et al. Population prevalence of the MELAS A3243G mutation. Mitochondrion 2007;7:230-233. (Pubitemid 46420125)
15. Elliott HR, Samuels DC, Eden JA, et al. Pathogenic mitochondrial DNA mutations are common in the general population. Am. J. Hum. Genet. 2008;83:254-260.
16. Santorelli FM, Shanske S, Macaya A, et al. The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh syndrome. Ann Neurol. 1993;34:827-834. (Pubitemid 23357897)
17. Holt IJ, Harding AE, Petty RK, Morgan Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet. 1990;46:428-433.
18. Carelli V, Barboni P, Sadun AA. Mitochondrial ophthalmology. In: DiMauro S, Hirano M, Schon EA, eds. Mitochondrial Medicine. London: Informa Healthcare, 2006:105-142.
19. Andreu AL, Hanna MG, Reichmann H, et al. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. New Engl. J. Med. 1999;341:1037-1044. (Pubitemid 29451799)
20. Massa V, Fernandez-Vizarra E, Alshahwan S, et al. Severe infantile encephalomyopathy caused by a mutation in COX6B1, a nucleus-encoded subunit of cytochrome c oxidase. Am. J. Hum. Genet. 2008;doi:10.1016/j.ajhg.2008.05.002.
21. Di Giovanni S, Mirabella M, Spinazzola A, et al. Coenzyme Q10 reverses pathological phenotype and reduces apoptosis in familial CoQ10 deficiency. Neurology 2001;57:515-518. (Pubitemid 32757603)
22. Sobreira C, Hirano M, Shanske S, et al. Mitochondrial encephalomyopathy with coenzyme Q10 deficiency. Neurology 1997;48:1238-1243. (Pubitemid 27240541)
23. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Nat Acad Sci USA 1989;86:2379-2382. (Pubitemid 19102512)
24. Gironi M, Lamperti C, Nemni R, et al. Late-onset cerebellar ataxia with hypogonadism and muscle coenzyme Q10 deficiency. Neurology 2004;62:818-820. (Pubitemid 38298968)
25. Lamperti C, Naini A, Hirano M, et al. Cerebellar ataxia and coenzyme Q10 deficiency. Neurology 2003;60:1206-1208. (Pubitemid 36418793)
26. Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-855. (Pubitemid 32290800)
27. Lalani S, Vladutiu GD, Plunkett K, et al. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch Neurol 2005;62:317-320. (Pubitemid 40204756)
28. Salviati L, Sacconi S, Murer L, et al. Infantile encephalomyopathy and nephropathy with CoQ10 deficiency: a CoQ10-responsive condition. Neurology 2005;65:606-608. (Pubitemid 41170725)
29. Rotig A, Appelkvist E-L, Geromel V, et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000;356:391-395. (Pubitemid 30487496)
30. Van Maldergem L, Trijbels F, DiMauro S, et al. Coenzyme Q-responsive Leigh's encephalopathy in two sisters. Ann Neurol 2002;52:750-754. (Pubitemid 35403184)
31. Diomedi-Camassei F, Di Giandomenico S, Santorelli F, et al. COQ2 nephropathy: A newly described inherited mitochondriopathy with primary renal involvement. J Am Soc Nephrol 2007;18:2773-2780. (Pubitemid 47531205)
32. Quinzii C, Kattah AG, Naini A, et al. Coenzyme Q deficiency and cerebellar ataxia associated with an aprataxin mutation. Neurology 2005;64:539-541. (Pubitemid 40189878)
33. Gempel K, Topaloglu H, Talim B, et al. The myopathic form of coenzyme Q10 deficiency is caused by mutations in the electron-transferring-flavoprotein dehydrogenase (ETFDH) gene. Brain 2007;130:2037-2044. (Pubitemid 47236610)
34. Lopez LC, Quinzii C, Schuelke M, et al. Leigh syndrome with nephropathy and CoQ10 deficiency due to decaproneyl diphosphate synthase subunit 2 (PDSS2) mutations. Am. J. Hum. Genet. 2006;79:1125-1129. (Pubitemid 44853484)
35. Mollet J, Giurgea I, Schlemmer D, et al. Prenyldiphosphate synthase (PDSS1) and OHbenzoate prenyltransferase (COQ2) mutations in ubiquinone deficiency and oxidative phosphorylation disorders. J. Clin. Invest. 2007;117:765-772. (Pubitemid 46348535)
36. Quinzii C, Naini A, Salviati L, et al. A mutation in para-Hydoxybenzoate- polyprenyl transferase (COQ2) causes primary coenzyme Q10 deficiency. Am. J. Hum. Genet. 2006;78:345-349. (Pubitemid 43157573)
37. Lagier-Tourenne C, Tazir M, Lopez LC, et al. ADSK3, an ancestral kinase, is mutated in a form of recessive ataxia associated with coenzyme Q10 deficiency. Am. J. Hum. Genet. 2008;82:661-672. (Pubitemid 351735958)
38. Mollet J, Delahodde A, Serre V, et al. CABC1 gene mutations cause ubiquinone deficiency with cerebellar ataxia and seizures. Am. J. Hum. Genet. 2008;82:623-630. (Pubitemid 351735957)
39. DiMauro S, Schon EA.Mitochondrial disorders in the nervous system. Annu. Rev. Neurosci. 2008;31:91-123.
40. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999;283:689-692.
41. Hirano M, Silvestri G, Blake D, et al. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical, biochemical and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994;44:721-727. (Pubitemid 24130006)
42. Kaukonen J, Juselius JK, Tiranti V, et al. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000;289:782-785. (Pubitemid 30650199)
43. Spelbrink JN, Li FY, Tiranti V, et al. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nature Genet. 2001;28:200-201.
44. Van Goethem G, Dermaut B, Lofgren A, et al. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nature Genet. 2001;28:211-212. (Pubitemid 32626018)
45. Graziewicz MA, Longley MJ, Copeland WC. DNA polymerade gamma in mitochondrial DNA replication and repair. Chem. Rev. 2006;106:385-405.
46. Longley MJ, Clark S, Man CYW, et al. Mutant POLG2 disrupts DNA polymerase gamma subunits and causes progressive external ophthalmoplegia. Am. J. Hum. Genet. 2006;78:1026-1034. (Pubitemid 43787693)
47. Zanna C, Ghelli A, Porcelli AM, et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008;131: 352-367. (Pubitemid 351197625)
48. Ferraris S, Clark S, Garelli E, et al. Perogressive external ophthalmoplegia and vision and hearing loss in a patient with mutations in POLG2 and OPA1. Arch. Neurol. 2008;65: 125-131.
49. Hudson G, Amati-Bonneau P, Blakeley E, et al. Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance. Brain 2007;131:329-337. (Pubitemid 351197604)
50. Amati-Bonneau P, Guichet A, Olichon A, et al. OPA1 R445H mutation in optic atrophy associated with sensorinaural deafness. Ann. Neurol. 2005;58:958-963. (Pubitemid 41746888)
51. Spinazzola A, Zeviani M. Disorders of nuclear-mitochondrial intergenomic signaling. Gene 2005;354:162-168. (Pubitemid 41116697)
52. Oskoui M, Davidzon G, Pascual J, et al. Clinical spectrum of mitochondrial DNA depletion due to mutations in the thymidine kinase 2 gene. Arch. Neurol. 2006;63: 1122-1126. (Pubitemid 44232318)
53. Ostergaard E, Christensen E, Kristensen E, et al. Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion. Am. J. Hum. Genet. 2007;81:383-387. (Pubitemid 47236085)
54. Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am. J. Hum. Genet. 2005;76:1081-1086. (Pubitemid 40705442)
55. Freisinger P, Futterer N, Lankes E, et al. Hepatocerebral mitochondrial DNA depletion syndrome caused by deoxyguanosine kinase (DGUOK) mutations. Arch. Neurol. 2006;63:1129-1134. (Pubitemid 44232319)
56. Mandel H, Szargel R, Labay V, et al. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nature Genet. 2001;29: 337-341. (Pubitemid 33096462)
57. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion. Ann Neurol. 2004;55:706-712. (Pubitemid 38544331)
58. Spinazzola A, Viscomi C, Fernandez-Vizarra E, et al. MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion. . Nature Genet. 2006;38:570-575.
59. Karadimas CL, Vu TH, Holve SA, et al. Navajo neurohepatopathy is caused by a mutation in the MPV17 gene. Am. J. Hum. Genet. 2006;79:544-548. (Pubitemid 44384263)
60. Jacobs HT, Turnbull DM. Nuclear genes and mitochondrial translation: a new class of genetic disease. Trends Genet. 2005;21:312-314. (Pubitemid 40726384)
61. Antonicka H, Sasarman F, Kennaway NG, Shoubridge EA. The molecular basis for tissue specificity of the oxidative phosphorylation deficiencies in patients with mutations in the mitochondrial translation factor EFG1. Hum. Mol. Genet. 2006;15:1835-1846. (Pubitemid 43821774)
62. Miller C, Saada A, Shaul N, et al. Defective mitochondrial translation caused by a ribosomal protein (MRPS16) mutation. Ann. Neurol. 2004;56:734-738. (Pubitemid 39540758)
63. Smeitink JAM, Elpeleg O, Antonicka H, et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am. J. Hum. Genet. 2006;79:869-877. (Pubitemid 44763401)
64. Fernandez-Vizarra E, Berardinelli A, Valente L, et al. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anemia (MLASA). J. Med. Genet. 2007;44:173-180. (Pubitemid 46580526)
65. Bykhovskaya Y, Casas KA, Mengesha E, et al. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am. J. Hum. Genet. 2004;74:1303-1308. (Pubitemid 38669331)
66. Scheper GC, van der Klok T, van Andel RJ. et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nature Genet. 2007;39:534-538.
67. Chan DC. Mitochondrial dynamics in disease. New Engl. J. Med. 2007;356:1707-1709. (Pubitemid 46658702)
68. Fichera M, Lo Giudice M, Falco M, et al. Evidence of kinesin heavy chain (KIF5A) involvement in pure hereditary spastic paraplegia. Neurology 2004;63: 1108-1110. (Pubitemid 39287929)
69. Delettre C, Lenaers G, Griffoin J-M, et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nature Genet. 2000;26: 207-210.
70. Alexander C, Votruba M, Pesch UEA, et al. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nature Genet. 2000;26:211-215.
71. Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005;65:197-204. (Pubitemid 41022361)
72. Zuchner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nature Genet. 2004;36: 449-451. (Pubitemid 38620027)
73. Pedrola L, Espert A, Wu X, et al. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum. Mol. Genet. 2005;14:1087-1094. (Pubitemid 40575884)
74. Niemann A, Ruegg M, La Padula V, et al. Ganglioside-induced differentiation associated protein 1 is a regulator of the mitochondrial network: new implications for Charcot-Marie-Tooth disease. J. Cell Biol. 2005;170:1067-1078. (Pubitemid 41362639)
75. Barth PG, Wanders RJA, Vreken P, et al. X-linked cardioskeletal myopathy and neutropenia (Barth syndrome) (MIM 30260). J. Inher. Metab. Dis. 1999;22:555-567. (Pubitemid 29281043)
76. Bione S, D'Adamo P, Maestrini E, et al. A novel X-linked gene, G4.5, is responsible for Barth syndrome. Nature Genet. 1996;12:385-389. (Pubitemid 26106250)
77. Schlame M, Ren M. Barth syndrome, a human disorder of cardiolipin metabolism. FEBS Lett. 2006;580:5450-5455. (Pubitemid 44465900)
78. Parone PA, Da Cruz S, Tondera D, et al. Preventing mitochondrial fission impairs mitochondrial function and leads to loss of mitochondrial DNA. PLoS ONE 2008;3:e3257.
79. King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 1989;246:500-503. (Pubitemid 19273941)
80. Chomyn A, Martinuzzi A, Yoneda M, et al. MELAS mutation in mtDNA binding site for transcription termination factor causes defects in protein synthesis and in respiration but no change in levels of upstream and downstream mature transcripts. Proc. Natl. Acad. Sci. USA 1992;89:4221-4225.
81. Chinnery PF, Taylor DJ, Brown DT, et al. Very low levels of the mtDNA A3243G mutation associated with mitochondrial dysfunction in vivo. Ann. Neurol. 2000;47:381-384. (Pubitemid 30141851)
82. Kaufmann P, Shungu D, Sano MC, et al. Cerebral lactic acidosis correlates with neurological impairment in MELAS. Neurology 2004;62:1297-1302. (Pubitemid 38526040)
83. Tatuch Y, Christodoulou J, Feigenbaum A, et al. Heteroplasmic mtDNA mutation (T>G) at 8993 can cause Leigh disease when the percentage of abnormal mtDNA is high. Am. J. Hum. Genet. 1992;50:852-858.
84. Carelli V, Baracca A, Barogi S, et al. Biochemical-clinical correlation in patients with different loads of the mitochondrial DNA T8993G mutation. Arch. Neurol. 2002;59: 264-270. (Pubitemid 34240943)
85. Sgarbi G, Baracca A, Lenaz G, et al. Inefficient coupling between proton transport and ATP synthesis may be the pathogenic mechanism for NARP and Leigh syndrome resulting from the T8993G mutation in mtDNA. Biochem. J. 2006;395:493-500.
86. Tanji K, Schon EA, DiMauro S, Bonilla E. Kearns-Sayre syndrome: oncocytic transformation of choroid plexus epithelium. J. Neurol. Sci. 2000;178:29-36.
87. Betts J, Jaros E, Perry RH, et al. Molecular neuropathology of MELAS: level of heteroplasmy in individual meurones and evidence of extensive vascular involvement. Neuropath Appl. Neurobiol. 2006;32:359-373. (Pubitemid 44015578)
88. Tanji K, Kunimatsu T, Vu TH, Bonilla E. Neuropathological features of mitochondrial disorders. Cell Develop. Biol. 2001;12:429-439.
89. Sacconi S, Salviati L, Nishigaki Y, et al. A functionally dominant mitochondrial DNA mutation. Hum. Mol. Genet. 2008;17:1814-1820. (Pubitemid 351791508)
90. Schon EA, Santra S, Pallotti F, Girvin ME. Pathogenesis of primary defects in mitochondrial ATP synthesis. Cell Develop. Biol. 2001;12:441-448.
91. Tatuch Y, Pagon RA, Vlcek B, et al. The 8993 mtDNA mutation: heteroplasmy and clinical presentation in three families. Eur. J. Hum. Genet. 1994.
92. Carrozzo R, Tessa A, Vazquez-Memije ME, et al. The T9176G mtDNA mutation affects ATP production and results in Leigh syndrome. Neurology 2001;56:687-690. (Pubitemid 32210012)
93. Thyagarajan D, Shanske S, Vazquez-Memije M, et al. A novel mitochondrial ATPase 6 point mutation in familial bilateral striatal necrosis. Ann. Neurol. 1995;38: 468-472.
94. Vazquez-Memije ME, Shanske S, Santorelli FM, et al. Comparative biochemical studies of ATPases in cells from patients with the T8993G or T8993C mitochondrial DNA mutations. J. Inher. Metab. Dis. 1998;21:829-836. (Pubitemid 28558679)
95. Solaini G, Harris DA, Lenaz G, et al. The study of the pathogenic mechanism of mitochondrial diseases provides information on basic bioenergetics. Biochim. Biophys. Acta. 2008;1777:941-945.
96. Baracca A, Sgarbi G, Mattiazzi M, et al. Biochemical phenotypes associated with the mitochondrial ATP6 gene mutations at nt8993. Biochim. Biophys. Acta. 2007;1767: 913-919. (Pubitemid 47031105)
97. Pallotti F, Baracca A, Hernandez-Rosa E, et al. Biochemical analysis of respiratory function in cybrid cell lines harbouring mitochondrial DNA mutations. Biochem. J. 2004;384: 287-293. (Pubitemid 39656241)
98. Carrozzo R, Murray J, Santorelli F, Capaldi RA. The T9176G mutation of human mtDNA gives fully assembled but inactive ATP synthase when modeled in Escherichia Coli. FEBS Lett. 2000;486:297-299.
99. Cortes-Hernandez P, Vazquez-Memije ME, Garcia JJ. ATP6 homoplasmic mutation inhibit and destabilize the human F1F0-ATP synthease without preventing enzyme assembly and oligomerization. J. Biol. Chem. 2007;282:1051-1058. (Pubitemid 47076544)
100. Garcia JJ, Ogilvie I, Robinson BH, Capaldi RA. Structure, function, and assembly of the ATP synthase in cells from patients with the T8993G mitochondrial DNA mutation. J. Biol. Chem. 2000;275:11075-11081.
101. Kirino Y, Yasukawa T, Ohta S, et al. Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc. Natl. Acad. Sci. USA 2004;101:15070-15075. (Pubitemid 39391720)
102. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J. Bioenerg. Biomembr. 1997;29:131-149. (Pubitemid 27314972)
103. DiMauro S, Bonilla E, Mancuso M, et al. Mitochondrial myopathies. Basic Appl. Mol. 2003;13:145-155. (Pubitemid 36892001)
104. Taylor RW, Giordano C, Davidson MM, et al. A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited cardiomyopathy. J. Am. Coll. Cardiol. 2003;41:1786-1796. (Pubitemid 36584254)
105. McFarland R, Schaefer AM, Gardner A, et al. Familial myopathy: New insights into the T14709C mitochondrial tRNA mutation. Ann. Neurol. 2004;55:478-484. (Pubitemid 38391964)
106. Shankar SP, Fingert JH, Carelli V, et al. Evidence for a novel X-linked modifier locus for Leber hereditary optic neuropathy. Opthal. Genet. 2008;29:17-24. (Pubitemid 351431243)
107. Hudson G, Keers S, Man PYW, et al. Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder. Am. J. Hum. Genet. 2005;77:1086-1091. (Pubitemid 41698527)
108. Papadopoulou LC, Sue CM, Davidson MM, et al. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nature Genet. 1999;23:333-337. (Pubitemid 29526433)
109. Valnot I, Osmond S, Gigarel N, et al. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am. J. Hum. Genet. 2000;67:1104-1109.
110. Wallace DC. The mitochondrial genome in human adaptive radiation and disease: On the road to therapeutics and performance enhancement. Gene 2005;354:169-180. (Pubitemid 41116698)
111. Hudson G, Carelli V, Spruijt L, et al. Clinical expression of Leber Hereditary optic neuropahy is affected by the mitochondrial DNA-haplogroup background. Am. J. Hum. Genet. 2007;81:228-233. (Pubitemid 47236071)
112. Lodi R, Carelli V, Cortelli P, et al. Phosphorus MR spectroscopy shows a tissue specific in vivo distribution of biochemical expression of the G3460A mutation in Leber's hereditary optic neuropathy. J. Neurol. Neurosurg. Psychiat. 2002;72:805-807. (Pubitemid 34557030)
113. Cortelli P, Montagna P, Pierangeli G, et al. Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical amd 31PMRS study. J. Neurol. Sci. 1997;148:25-31. (Pubitemid 27149521)
114. Valentino ML, Barboni P, Rengo C, et al. The 13042G>A/ND5 mutation in mtDNA is pathogenic and can be associated also with a prevalent ocular phenotype. J. Med. Genet. 2006;43:e38.
115. Barbiroli B, Iotti S, Lodi R. Improved brain and muscle mitochondrial respiration with CoQ. An in vivo study by 31P-MR spectroscopy in patients with mitochondrial cytopathies. BioFactors 1999;9:253-260. (Pubitemid 29289004)
116. Haller RG, Vissing J. Functional evaluation of metabolic myopathies. In: Engel AG, Franzini-Armstrong C, eds. Myology. Vol. 1. New York: McGraw-Hill, 2004:665-679.
117. Vazquez-Memije ME, Shanske S, Santorelli FM, et al. Comparative biochemical studies in fibroblasts from patients with different forms of Leigh syndrome. J. Inher. Metab. Dis. 1996;19:43-50. (Pubitemid 26085563)
118. Lenaz G, Baracca A, Carelli V, et al. Bioenergetics of mitochondrial diseases associated with mtDNA mutations. Biochim. Biophys. Acta. 2004;1658:89-94. (Pubitemid 39013238)
119. Baracca A, Barogi S, Carelli V, et al. Catalytic activities of mitochondrial ATP synthase in patients with mitochondrial DNA T8993G mutation in the ATPase 6 gene. J. Biol. Chem. 2000;275:4177-4182. (Pubitemid 30094652)
120. Baracca A, Solaini G, Sgarbi G, et al. Severe impairment of complex I-driven ATP synthesis in Leber's hereditary optic neuropathy cybrids. Arch. Neurol. 2005;62:730-736. (Pubitemid 40656087)
121. Carelli V, Rugolo M, Sgarbi G, et al. Bioenergetics shapes cellular death pathways in Leber's hereditary optic neuropathy: a model of mitochondrial neurodegeneration. Biochim. Biophys. Acta. 2004;1658:172-179. (Pubitemid 39013248)
122. Hirano M, DiMauro S. Leber's hereditary optic neuropathy: biochemical lights in a blurry scenario. Arch. Neurol. 2005;62:711-712. (Pubitemid 40656084)
123. Droge W. Free radicals in the physiologycal control of cell function. Physiol. Rev. 2002;82:47-95. (Pubitemid 34654215)
124. Verkaart S, Koopman WJH, van Emst-De Vries SE, et al. Superoxide production is inversely related to complex I activity in inherited complex I deficiency. Biochim. Biophys. Acta. 2007;1772:373-381. (Pubitemid 46275438)
125. Pitkanen S, Robinson BH. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J. Clin. Invest. 1996;98: 345-351. (Pubitemid 26255732)
126. Rimessi A, Giorgi C, Pinton P, Rizzuto R. The versatility of mitochondrial calcium signals: From stimulation of cell metabolism to induction of cell death. Biochim. Biophys. Acta. 2008;1777:808-816. (Pubitemid 351934610)
127. Brini M, Pinton P, King MP, et al. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nature Med. 1999;5:951-954. (Pubitemid 29372425)
128. Moudy AM, Handran SD, Goldberg MP, et al. Abnormal calcium homeostasis and mitochondrial polarization in a human encephalomyopathy. Proc. Natl. Acad. Sci. USA 1995;92:729-733.
129. Szadbadkai G, Simoni AM, Bianchi K, et al. Mitochondrial dynamics and Calcium signaling. Biochim. Biophys. Acta. 2006;1763:442-449.
130. Bianchi K, Rimessi A, Prandini A, et al. Calcium and mitochondria: mechanisms and functions of a troubled relationship. Biochim. Biophys. Acta. 2004;1742:119-131. (Pubitemid 39601772)
131. DiMauro S, Hirano M, Schon EA. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 2006;34:265-283. (Pubitemid 44300157)
132. Millhouse-Flourie TJ. Physical, occupational, respiratory, speech, equine, and pet therapies for mitochondrial disease. Mitochondrion 2004;4:549-558. (Pubitemid 39646805)
133. DiMauro S, Hirano M, Kaufmann P, Mann JJ. Mitochondrial psychiatry. In: DiMauro S, Hirano M, Schon EA, eds. Mitochondrial Medicine. London: Informa Healthcare, 2006:261-277.
134. Taivassalo T, Haller RG. Exercise and training in mitochondrial myopathies. Med. Sci. Sports Exerc. 2005;37:2094-2101. (Pubitemid 41780736)
135. Edmonds JL. Surgical and anesthetic management of patients with mitochondrial dysfunction. Mitochondrion 2004;4:543-548.
136. Sinnathurai AR, Raut V, Awa A, et al. A review of cochlear implantation in mitochondrial sensorineural hearing loss. Otolol. Neurol. 2003;24:418-426. (Pubitemid 36618164)
137. Bonnet D, Rustin P, Rotig A, et al. Heart transplantation in children with mitochondrial cardiomyopathy. Heart 2001;86:570-573.
138. Lee WS, Sokol RJ. Mitochondrial hepatopathies: Advances in genetics and pathogenesis. Hepatology 2007;45:1555-1565. (Pubitemid 46918340)
139. Rotig A, Niaudet P. Mitochondrial nephrology. In: DiMauro S, Hirano M, Schon EA, eds. Mitochondrial Medicine. London: Informa Healthcare, 2006:197-207.
140. White SL, Shanske S, McGill JJ, et al. Mitochondrial DNA mutations at nucleotide 8993 show a lack of tissue- or age-related variation. J. Inher. Metab. Dis. 1999;22: 899-914.
141. Blok RB, Gook DA, Thorburn DR, Dahl H-HM. Skewed segregation of the mtDNA nt 8993 (T>G) mutation in human oocytes. Am. J. Hum. Genet. 1997;60:1495-1501. (Pubitemid 27258083)
142. Sato A, Kono T, Nakada K, et al. Gene therapy for progeny of mito-mice carrying pathogenic mtDNA by nuclear transplantation. Proc. Natl. Acad. Sci. USA 2005;102: 16765-16770. (Pubitemid 41688851)
143. Hirano M, Marti R, Casali C, et al. Allogeneic stem cell transplantation corrects biochemical derangements in MNGIE. Neurology 2006;67:1458-1460. (Pubitemid 44632073)
144. Bastin J, Aubey F, Rotig A, et al. Activation of peroxisome proliferator-activated receptor pathway stimulates the mitochondrial respiratory chain and can correct deficiencies in patients' cells lacking its components. J. Clin. Endocrinol. Metab. 2008;93:1433-1441. (Pubitemid 351519745)
145. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008;8:249-255.
146. Chinnery PF, Taylor RW, Diekert K, et al. Peptide nucleic acid delivery to human mitochondria. Gene Therapy 1999;6:1919-1928. (Pubitemid 30076862)
147. Taylor RW, Chinnery PF, Turnbull DM, Lightowlers RN. Selective inhibition of mutant human mitochondrial DNA replication in vitro by peptide nucleic acids. Nature Genet. 1997;15:212-215. (Pubitemid 27061647)
148. Kolesnikova OA, Entelis NS, Jacquin-Becker C, et al. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERF syndrome in cultured human cells. Hum. Mol. Genet. 2004;13: 2519-2534. (Pubitemid 39377855)
149. Bai Y, Hajek P, Chomyn A, et al. Lack of complex I activity in human cells carrying a mutation in MtDNA-encoded ND4 subunit is corrected by the Saccharomyces cerevisiae NADH-quinone oxidoreductase (NDI1) gene. J. Biol. Chem. 2001;276: 38808-38813.
150. Manfredi G, Fu J, Ojaimi J, et al. Rescue of a deficiency in ATP synthesis by transfer of MTATP6, a mitochondrial DNA-encoded gene, to the nucleus. Nature Genet. 2002;30: 394-399.
151. Bonnet C, Augustin S, Ellouze S, et al. The optimized allotopic expression of ND1 or ND4 genes restores respiratory chain complex I activity in fibroblasts harboring mutations in these genes. Biochim. Biophys. Acta. 2008;1783:1707-1717.
152. Ellouze S, Augustin S, Bouaita A, et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am. J. Hum. Genet. 2008;83:373-387.
153. Hakkaart GA, Dassa EP, Jacobs HT, Rustin P. Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration. EMBO Rep. 2006;7:341-345.
154. Seo BB, Nakamura-Ogiso E, Flotte TR, et al. A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition. Mol. Ther. 2002;6:336-341. (Pubitemid 36305335)
155. Bacman SR, Williams SL, Hernandez D, Moraes CT. Modulating mtDNA heteroplasmy by mitochondria-targeted restriction endonucleases in a "differential multiple cleavage-site" model. Gene Ther. 2007;14:1309-1318. (Pubitemid 47365618)
156. Tanaka M, Borgeld HJ, Zhang J, et al. Gene therapy for mitochondrial disease by delivering restriction endonuclease SmaI into mitochondria. J. Biomed. Sci. 2002;9:534-541. (Pubitemid 35316865)
157. Minczuk M, Papworth MA, Miller JG, et al. DEvelopment of a single-chain, quasi-dimeric zinc-finger nuclease for the selective degradation of mutated human mitochondrial DNA. Nucleic Acids Res. 2008;36:3926-3938. (Pubitemid 351984809)
158. Sabatini S, Kurtzman NA. Bicarbonate therapy in severe metabolic acidosis. J. Am. Soc. Nephrol. 2008;doi:10.1681/ASN.2007121329.
159. Stacpoole PW. The pharmacology of dichloroacetate. Metabolism 1989;38:1124-1144. (Pubitemid 19273807)
160. Stacpoole PW, Gilbert LR, Neiberger RE, et al. Evaluation of long-term treatment of children with congenital lactic cidosis with dichloroacetate. Pediatrics 2008;121:e1223-e1228.
161. Stacpoole PW, Kerr DS, Barnes C, et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006;117:1519-1531. (Pubitemid 46071378)
162. Felitsyn N, Stacpoole PW, Notterpek L. Dichloroacetate causes reversible demyelination in vitro: potential mechanism for its neuropathic effect. J. Neurochem. 2007;100:429-436. (Pubitemid 46011003)
163. Kaufmann P, Engelstad K, Wei Y-H, et al. Dichloroacetate causes toxic neuropathy in MELAS: A randomized, controlled clinical trial. Neurology 2006;66:324-330. (Pubitemid 43739931)
164. Kaufmann P, Anziska Y, Gooch CL, et al. Nerve conduction annormalities in MELAS/3243 patients. Arch. Neurol. 2006;63:746-748.
165. Spinazzola A, Marti R, Nishino I, et al. Altered thymidine metabolism due to defects of thymidine phosphorylase. J. Biol. Chem. 2002;277:4128-4132.
166. Quinzii C, Lopez de Munain A, Von-Moltke J, et al. Respiratory chain dysfunction and oxidative stress correlate with severity of primary CoQ10 deficiency. FASEB J. 2008; in press.
167. Marriage BJ, ClandininMT, Macdonald IM, Glerum DM. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol. Genet. Metab. 2004;81:263-272. (Pubitemid 38429989)
168. Dougados M, Zitoun J, Laplane D, Castaigne P. Folate metabolism disorder in Kearns-Sayre syndrome. Ann. Neurol. 1983;13:687.
169. Allen RJ, DiMauro S, Coulter DL, et al. Kearns-Sayre syndrome with reduced plasma and cerebrospinal fluid folate. Ann Neurol. 1983;13:679-682. (Pubitemid 13103472)
170. Pineda M, Ormazabal A, Lopez-Gallardo E, et al. Cerebral folate deficiency and leukoencephalopathy caused by a mitochondrial DNA deletion. Ann. Neurol. 2006;59: 394-398. (Pubitemid 43202497)
171. Tarnopolsky MA, Roy BD, MacDonald JR. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 1997;20:1502-1509. (Pubitemid 27512338)
172. Klopstock T, Schlamp V, Schmidt F, et al. Creatine monohydrate in mitochondrial diseases: a double-blind, placebo-controlled, cross-over study in 16 patienrs with progressive external ophthalmoplegia or mitochondrial myopathy. Neurology 1999;52:A543-A544.
173. Tarnopolsky MA, Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 1999;22:1228-1233. (Pubitemid 29409691)
174. Baker SK, Tarnopolsky MA. Targeting cellular energy production in neurological disorders. Expert Opin. Investig. Drugs. 2003;12:1-24.
175. Di Prospero N, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial. Lancet Neurol. 2007;6:878-886. (Pubitemid 47404985)
176. Naini A, Kaufmann P, Shanske S, et al. Hypocitrullinemia in patients with MELAS: an insight into the "MELAS paradox". J. Neurol. Sci. 2005;229-230:187-193. (Pubitemid 40347254)
177. Koga Y, Akita Y, Nishioka J, et al. L-Arginine improves the symptoms of strokelike episodes in MELAS. Neurology 2005;64:710-712. (Pubitemid 40261903)
178. Koga Y, Akita Y, Junko N, et al. Endothelial dysfunction inMELAS improved by L-arginine supplementation. Neurology 2006;66:1766-1769. (Pubitemid 43964643)
179. Koga Y, Ishibashi M, Ueki I, et al. Effects of L-arginine on the acute phase of strokes in three patients with MELAS. Neurology 2002;58:827-828. (Pubitemid 34211569)
180. Kubota M, Sakakihara Y, Mori M, et al. Beneficial effect of L-arginine for stroke-like episode in MELAS. Brain Develop. 2004;26:481-483. (Pubitemid 39209388)